In the first-line setting, the Phase 3 KEYNOTE-024 trial randomised NSCLC patients with tumour PD-L1 expression of >50% to pembrolizumab versus standard-of-care platinum-based chemotherapy.45 The median OS was 30 versus 14.2 months, favouring pembrolizumab (death HR 0.49, 95% CI 0.34–0.69, adjusted for crossover). The gene discussed is CD274; the disease is neoplasm.